Another important finding is that key drug targets for NAFLD/NASH treatment are well expressed in hiPS-HEP, e.g., the peroxisome proliferator−activated receptor-α (PPARA) and -δ (PPARD), which are targets for the drug elafibranor [38], and the nuclear receptor FXR (NR1H4), which is a target for the drug obeticholic acid [39]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.